Antifungal Susceptibilities of Cryptococcus neoformans
Lennox K. Archibald*
1
, Marion J. Tuohy†, Deborah A. Wilson†, Okey Nwanyanwu‡, Peter N. Kazembe‡, Somsit Tansuphasawadikul§, Boonchuay Eampokalap§, Achara Chaovavanich§, L.Barth Reller¶, William R. Jarvis*, Gerri S. Hall†, and Gary W. Procop†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Cleveland Clinic Foundation, Cleveland, Ohio, USA; ‡Lilongwe Central Hospital, Lilongwe, Malawi; §Bamrasnaradura Hospital, Nonthaburi, Thailand; ¶Duke University Medical Center, Durham, North Carolina, USA
Main Article
Table 1
Cryptococcus neoformans susceptibility results
Antifungal agent |
MIC range (μg/mL) |
MIC50 (μg/mL) |
MIC90 (μg/mL) |
MIC geometric mean (μg/mL) |
U.S. isolates (N = 20) |
Amphotericin B |
1–2 |
1 |
2 |
1.4 |
Fluconazole |
1–16 |
8 |
8 |
5.1 |
Itraconazole |
0.016–0.125 |
0.06 |
0.125 |
0.06 |
5-Flucytosine |
2–8 |
4 |
8 |
5.1 |
Ketoconazole |
<0.008–0.250 |
0.06 |
0.06 |
0.05 |
Thailand isolates (N = 29) |
Amphotericin B |
0.5–2 |
1 |
2 |
1.2 |
Fluconazole |
4–160 |
8 |
16 |
7.7 |
Itraconazole |
0.030–0.125 |
0.06 |
0.06 |
0.06 |
5-Flucytosine |
2–8 |
4 |
8 |
4.6 |
Ketoconazole |
0.030–0.250 |
0.06 |
0.125 |
0.07 |
Malawi isolates (N = 16) |
Amphotericin B |
1–2 |
2 |
2 |
1.6 |
Fluconazole |
4–32 |
8 |
16 |
7.6 |
Itraconazole |
0.030–0.125 |
0.03 |
0.125 |
0.05 |
5-Flucytosine |
1–16 |
4 |
8 |
4.5 |
Ketoconazole |
0.016–0.250 |
0.03 |
0.25 |
0.03 |
Main Article
Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.